BIOKIMIA

LIPID

Nama kelompok:
Lalu doni urif Kusuma(2021E1C032)
Lalu teguh winatra(2021E1C077)
Lalu seflida lomata
Kanita naura salsabila(2021E1C031)
Ira puspita(2021E1C029)
Jihan imel faiha(2021E1C030)
johratu

PROGRAM STUDI S1 FARMASI

FAKULTAS ILMU KESEHATAN
UNIVERSITAS MUHAMMADIYAH MATARAM
TAHUN AJARAN
2021/2022
Biochemistry, Lipids
Saba Ahmed; Parini Shah; Owais Ahmed.

Last Update: May 8, 2022.

Introduction
Fats and lipids are an essential component of the homeostatic function of the human body.
Lipids contribute to some of the body’s most vital processes.
Lipids are fatty, waxy, or oily compounds that are soluble in organic solvents and insoluble in
polar solvents such as water. Lipids include:
 Fats and oils (triglycerides)
 Phospholipids
 Waxes
 Steroids

Fundamentals
Fats and oils are esters made up of glycerol (a 3-carbon sugar alcohol/polyol) and 3 fatty
acids. Fatty acids are hydrocarbon chains of differing lengths with various degrees of
saturation that end with carboxylic acid groups. Additionally, fatty acid double bonds can
either be cis or trans, creating many different types of fatty acids. Fatty acids in biological
systems usually contain an even number of carbon atoms and are typically 14 carbons to 24
carbons long. Triglycerides store energy, provide insulation to cells, and aid in the absorption
of fat-soluble vitamins. Fats are normally solid at room temperature, while oils are
generally liquid.[1]
Lipids are an essential component of the cell membrane. The structure is typically made of a
glycerol backbone, 2 fatty acid tails (hydrophobic), and a phosphate group (hydrophilic). As
such, phospholipids are amphipathic. In the cell membrane, phospholipids are arranged in a
bilayer manner, providing cell protection and serving as a barrier to certain molecules. The
hydrophilic part faces outward and the hydrophobic part faces inward. This arrangement
helps monitor which molecules can enter and exit the cell. For example, nonpolar molecules
and small polar molecules, such as oxygen and water, can easily diffuse in and out of the cell.
Large, polar molecules, for example, glucose, cannot pass freely so they need the help of
transport proteins.
Another type of lipid is wax. Waxes are esters made of long-chain alcohol and a fatty acid.
They provide protection, especially to plants in which wax covers the leaves of plants. In
humans, cerumen, also known as earwax, helps protect the skin of the ear canal.
A further class includes steroids, which have a structure of 4 fused rings. One important type
of steroid is cholesterol. Cholesterol is produced in the liver and is the forerunner to many
other steroid hormones, such as estrogen, testosterone, and cortisol. It is also a part of cell
membranes, inserting itself into the bilayer and influencing the membrane’s fluidity.[2]

Mechanism
The interaction between water-fearing and fat-loving displays more clearly during lipid
transport in plasma. Both cholesterol and triglycerides are nonpolar lipid molecules.
Therefore, they must travel in the polar plasma with the help of lipoprotein particles. The
main goal of lipoprotein is to help transport lipids (hydrophobic) in water. The structure of
lipoprotein consists of triglycerides, cholesterol, phospholipids, and apolipoproteins.
Apolipoproteins mainly function as carrier proteins but also serve as cofactors for enzymes
that metabolize lipoproteins and help in lipid component exchange among lipoproteins. Some
examples of lipoproteins include chylomicrons, very-low-density lipoproteins (VLDL),
intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density
lipoproteins (HDL). Each one is used in a different phase of lipid transport.[3]
Chylomicrons are large triglyceride-rich particle made in the endoplasmic reticulum of
enterocytes of the small intestine. They play a role in carrying dietary triglycerides and
cholesterol to peripheral tissues and the liver.[4] Apo B-48 is an apolipoprotein that is
involved in chylomicron assembly, thus having a vital role in the absorption of dietary fats
and fat-soluble vitamins.[5]
VLDLs are triglyceride-rich particles made in the liver.[4] Apo B-100 is important for VLDL
production.[5]
IDL particles, which are cholesterol-rich, are created when triglycerides are removed from
VLDL by muscle and adipose tissue.[4]
LDL particles are formed from VLDL and IDL particles and are also rich in cholesterol. LDL
transports most of the cholesterol in the blood and is colloquially considered “bad
cholesterol.”[4] Apo B-100 plays a key role by acting as a ligand for the LDL receptor-
mediated uptake of LDL particles by the liver and other tissues.[5]
HDL particles are cholesterol and phospholipid-rich, and aid in reverse cholesterol transport
from peripheral tissues to the liver, where it is removed. As such, HDL cholesterol is
considered “good cholesterol”.[4]
To expand, the transport of plasma lipids involves two routes. One is an exogenous path for
the transport of dietary triglycerides and cholesterol from the small intestine.[3] In the small
intestine, triglycerides are broken down with the help of enzymes and bile acids, such as
cholic acid. First, the early digestive products, such as free fatty acids, trigger release of the
hormone Cholecystokinin (CCK) by the duodenum. CCK activity stimulates emptying of the
gallbladder, which leads to bile release into the small intestine, and further triggers the
pancreas to release pancreatic digestive enzymes into the intestine.[6] The detergent action of
bile acids helps to emulsify fats, which allows easier hydrolysis by water-soluble digestive
enzymes due to the increased surface area. One important enzyme, pancreatic lipase, breaks
down triglycerides to produce free fatty acids and monoacylglycerol, which are absorbed by
the intestinal mucosal cells with the help of mixed micelles that were created in the process.
[7]
Fatty acids are made of 12 carbons or less and are absorbed through the intestinal mucosal
villi. They enter the bloodstream through capillaries, reach the portal vein, and are taken to
the liver with the help of lipid carrier proteins to be used for energy. However, longer-chain
fatty acids are absorbed by the intestinal mucosa from the lumen, where they are re-esterified
to form triglycerides and are incorporated into chylomicrons; the chylomicrons are then
released into intestinal lymph, secreted into blood circulation through the thoracic duct, and
attach to capillary walls in adipose and skeletal muscle tissue. At the attachment points,
chylomicrons interact with the enzyme lipoprotein lipase, leading to triglyceride core
breakdown and free fatty acid release. The fatty acids penetrate through the capillary
endothelial cells and are either stored in adipose cells or oxidized in skeletal muscle cells.
From the triglyceride core hydrolysis, remnants are removed from the plasma and brought to
hepatic cells to be broken down by lysosomes. This causes the release of cholesterol, which
can be turned into bile acids, integrated into VLDL, or even combined in bile.
The other pathway is via the endogenous system, in which cholesterol and triglycerides travel
from the liver and other non-intestinal tissues into circulation. The liver produces
triglycerides from carbohydrates and free fatty acids. These triglycerides are then released
into plasma in the core of VLDL. The VLDL particles interact with lipoprotein lipase in
tissue capillaries, causing triglyceride core hydrolysis and free fatty acid liberation. Some of
the remnant particles are taken out of plasma and bind to hepatic cells. The rest of the
remnant particles, however, transform into LDL particles, which then provide cholesterol to
cells that have LDL receptors, such as the gonads, adrenal glands, skeletal muscle,
lymphocytes, and kidneys.
In addition to the functions mentioned above, when energy is needed, fat can also be broken
down for energy. Glucagon (released during fasting) or epinephrine (released during
exercise) activates adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), and
monoglyceride lipase (MGL) for fatty acid liberation. These fatty acids can then be used for
energy by most tissues with the help of mitochondria and the Krebs cycle.[3]

Testing
Tests can be performed to determine the levels of the different types of lipids in the blood.
While cholesterol levels are usually steady, triglyceride levels vary from day to day and rise
after meals. Therefore, a blood sample called a “lipid panel" taken for lipid testing should
occur after a 12-hour fasting period, which allows the clearance of chylomicrons from the
blood. For more accurate results, patients should not take any medications that could
change blood lipid levels or take the test during times of stress or illness.[3]

Clinical Significance
Abnormal levels of cholesterol and triglycerides in the blood are often due to the
unusual assembly, breakdown, or transport of their lipoprotein particles. An increased level
of plasma lipoproteins is termed hyperlipoproteinemia, while the decreased level of plasma
lipoproteins is termed hypolipoproteinemia.
Levels of plasma lipids are good indicators of the risk of cardiovascular disease (CVD). For
instance, hyperlipoproteinemia is related to a greater risk of atherosclerotic cardiovascular
disease, as well as a higher occurrence of ischemic vascular disease and development of fatty
deposits under the skin, known as xanthomas and xanthelasmas. Elevated plasma
concentrations of total cholesterol and LDL are linked with an increased risk of coronary
heart disease and raised plasma triglycerides.  An increase in VLDL is related to a greater
prevalence of atherosclerotic heart disease. However, elevated levels of HDL cholesterol may
protect against atherosclerotic heart disease, due to its ability to prevent excessive
accumulation of cholesterol in the body. There are several types and subtypes of lipid-related
disorders and they are described below.
Hypertriglyceridemia is a disorder with high levels of triglycerides in the blood. Five main
disorders result in hypertriglyceridemia:
  Familial hypertriglyceridemia: An autosomal dominant disorder that results
in elevated VLDL levels in plasma
 Familial combined hyperlipidemia: An autosomal dominant disorder, characterized by
the excessive synthesis of lipoproteins containing apolipoprotein B
 Congenital lipoprotein lipase deficiency: An autosomal recessive disorder, which
results in low to no lipoprotein lipase activity; typically, chylomicrons build up in the
blood and eruptive xanthomas develop   
 Apoprotein CII deficiency: An autosomal recessive disorder, characterized by the lack
of apoprotein CII, an essential cofactor for lipoprotein lipase activity; there is usually
chylomicron and VLDL accumulation in the plasma
 Familial dysbetalipoproteinemia: A disorder in which there is a defect in
apolipoprotein E; due to the buildup of remnant VLDL particles in the blood, there
are higher plasma levels of cholesterol and triglyceride
Hypercholesterolemia is a disorder in which there are high cholesterol levels in the
blood. Three main conditions result in hypercholesterolemia:
 Polygenic hypercholesterolemia: The most common disorder to raise cholesterol
levels; there are many genes involved that elevate LDL concentration in plasma
 Familial hypercholesterolemia: An autosomal dominant disorder in which the gene for
the LDL receptor is defective, so removal of LDL from plasma is less than effective
 Familial combined hyperlipidemia: Discussed previously above
Hyperalphalipoproteinemia is a disorder with elevated HDL levels in the plasma. Most cases
are inherited through a dominant or polygenic manner and are linked to a lower risk of
coronary artery disease.[8]
High levels of plasma lipids can also be due to dietary factors, such as ingesting excess
calories, saturated fatty acids, and cholesterol, as well as from medication use.
Hypolipoproteinemia refers to relatively low levels of lipids in the blood. Such a condition
may be associated with a genetic component or perhaps other conditions like anemia or an
overactive thyroid.
Hypolipoproteinemias include three primary conditions:
 Hypoalphalipoproteinemia: A reduction in HDL cholesterol levels in plasma that is
associated with a greater risk of coronary heart disease
 Abetalipoproteinemia: An autosomal recessive disease; it is caused by apoprotein B
deficiency and is characterized by the lack of chylomicrons, LDL, and VLDL in the
blood
 Tangier disease: An autosomal recessive disorder classified by an absence of plasma
HDL, which results in the synthesis of abnormal chylomicron remnant
Other disorders in which abnormal structural lipoproteins and their concentrations are present
in the blood are referred to as dyslipoproteinemia. One disorder of this kind is LCAT
(lecithin-cholesterol acyltransferase) deficiency. Low activity of this enzyme
causes unesterified cholesterol to accumulate in plasma and tissues.[3]
Further diseases include lipid storage diseases, or lipidoses, which are genetic diseases in
which atypical amounts of lipids accumulate in cells and tissues. Lipidoses are characterized
by the absence of enzymes needed to metabolize lipids or a defect in the proper functioning
of enzymes. This abnormal fat deposition can lead to severe damage in cells and tissues,
including the brain, heart, liver, kidney, and spleen. Two examples of lipidoses include
Gaucher disease and Tay-Sachs disease. Gaucher disease is caused by a deficiency in the
enzyme glucocerebrosidase, resulting in hepatosplenomegaly, pancytopenia, and bone crises.
Tay-Sachs is caused by the absence of the enzyme hexosaminidase-A and leads to a
progressive loss of mental and physical capabilities.[9]
While treatment for lipidoses is unspecific and mainly limited to enzyme replacement
therapy, there are medication options that help lower lipid plasma levels. However, it is of the
utmost importance to manage dietary consumption and lifestyle changes either before or in
conjunction with starting medication. Some of these changes may include a reduced-calorie
diet, exercise, and quitting smoking if one is a smoker. Popular medication options include
statins, fibrates, omega-3 fatty acids, bile acid sequestrants, a cholesterol-absorption inhibitor,
and nicotinic acid. Of these choices, statins are the most widely prescribed treatment.
[10] They can lower cholesterol biosynthesis, primarily in the liver by competitively
inhibiting HMG-CoA reductase, the rate-limiting enzyme for cholesterol production. Statins
also aid in the uptake and destruction of LDL. They have contributed to the progress made in
the primary and secondary prevention of coronary heart disease, and have lowered death
rates in coronary patients.[11]

References
1.Panickar KS, Bhathena SJ. Control of Fatty Acid Intake and the Role of Essential Fatty
Acids in Cognitive Function and Neurological Disorders. In: Montmayeur JP, le Coutre J,
editors. Fat Detection: Taste, Texture, and Post Ingestive Effects. CRC Press/Taylor &
Francis; Boca Raton (FL): 2010. [PubMed]
2.Watson H. Biological membranes. Essays Biochem. 2015;59:43-69. [PMC free article]
[PubMed]
3.Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins.
In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and
Laboratory Examinations. 3rd ed. Butterworths; Boston: 1990. [PubMed]
4.Feingold KR. Introduction to Lipids and Lipoproteins. In: Feingold KR, Anawalt B,
Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J,
Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B,
Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F,
Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext
[Internet]. MDText.com, Inc.; South Dartmouth (MA): Jan 19, 2021. [PubMed]
5.Young SG. Recent progress in understanding apolipoprotein B. Circulation. 1990
Nov;82(5):1574-94. [PubMed]
6.Otsuki M. Pathophysiological role of cholecystokinin in humans. J Gastroenterol
Hepatol. 2000 Mar;15 Suppl:D71-83. [PubMed]
7.Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical
responses to bile acid sequestration. Diabetes Care. 2009 Nov;32 Suppl 2:S237-45. [PMC
free article] [PubMed]
8.Fras Z. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the
challenges of current and future therapeutic possibilities. Anatol J Cardiol. 2020
Jan;23(2):60-69. [PMC free article] [PubMed]
9.Schulze H, Sandhoff K. Lysosomal lipid storage diseases. Cold Spring Harb Perspect
Biol. 2011 Jun 01;3(6) [PMC free article] [PubMed]
10.Egom EE, Hafeez H. Biochemistry of Statins. Adv Clin Chem. 2016;73:127-
68. [PubMed]
11.Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001 Oct-
Dec;5(4):378-87. [PMC free article] [PubMed]